Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $351000.0.

  • Contineum Therapeutics' Change in Accured Expenses fell 7089.55% to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $325000.0, marking a year-over-year increase of 11450.89%. This contributed to the annual value of $2.3 million for FY2024, which is 4447.93% up from last year.
  • Contineum Therapeutics' Change in Accured Expenses amounted to $351000.0 in Q3 2025, which was down 7089.55% from -$102000.0 recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Change in Accured Expenses peaked at $2.9 million during Q4 2024, and registered a low of -$2.9 million during Q1 2025.
  • Its 3-year average for Change in Accured Expenses is $116727.3, with a median of -$102000.0 in 2025.
  • In the last 5 years, Contineum Therapeutics' Change in Accured Expenses skyrocketed by 28305.3% in 2024 and then plummeted by 65315.79% in 2025.
  • Contineum Therapeutics' Change in Accured Expenses (Quarter) stood at -$1.6 million in 2023, then surged by 283.05% to $2.9 million in 2024, then tumbled by 88.05% to $351000.0 in 2025.
  • Its Change in Accured Expenses was $351000.0 in Q3 2025, compared to -$102000.0 in Q2 2025 and -$2.9 million in Q1 2025.